Table 3

Kaplan–Meier product-limit (survival) analysis

Median survival (months) (95% confidence interval)Wilcoxon χ2p ValueComment
Overall survival by metastasis-free interval
    <1 year19.0 (7.5 to 29.6)67.07<0.0001
    1–5 years61.1 (37.8 to 48.4)
    >5 years145.7 (108.1 to 141.6)
Metastatic survival by metastasis-free interval
    <1 year11.4 (0.0 to 29.5)4.830.0893All groups
    1–5 years25.6 (7.3 to 17.7)
    >5 years45.1 (0.0 to 54.6)5.210.0225<1 versus >5
Metastasis-free interval
    Non-operated patients35.0 (21.3 to 48.1)0.700.4035
    Operated patients37.0 (18.9 to 58.9)
Metastatic survival
    Non-operated patients6.8 (3.6 to 12.5)14.460.0001
    Operated patients23.0 (13.3 to 41.3)
Postoperative survival by no of liver metastases
    181.3 (22.2 to 141.4)11.720.0028
    2–529.7 (4.4 to 41.5)
    ⩾615.3 (11.4 to 15.1)
    1–555.2 (0.0 to 91.6)9.090.00261–5 versus ⩾6
Postoperative survival by surgical borders
    R065.6 (11.5 to)2.180.1401
    R1/R216.6 (7.6 to 25.5)